Seikagaku Corp
Company Profile
Business description
Seikagaku Corp makes and sells pharmaceuticals and medical devices related to glycoconjugates. The firm operates in two segments: pharmaceutical and LAL. The pharmaceutical segment contributes the majority of revenue. This business sells pharmaceutical products made from hyaluronic acid, a major component of glycoconjugates, as well as medical devices and bulk products. The LAL segment manufactures endotoxin-detecting reagents made from limulus amebocyte lysate that are used to control quality in the pharmaceutical manufacturing process. Seikagaku generates the majority of its sales in Japan.
Contact
Marunouchi Center Building 10 Floor
6-1, Marunouchi 1-chome, Chiyoda-ku
Tokyo100-0005
JPNT: +81 352208950
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 March 2025
Employees
1,090
Stocks News & Analysis
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
stocks
Is this overpriced ASX share too much of a gamble?
stocks
ASX players that might thrive under a Trump administration
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,520.90 | 41.00 | 0.48% |
| CAC 40 | 7,311.80 | 94.97 | 1.32% |
| DAX 40 | 19,263.70 | 260.59 | 1.37% |
| Dow JONES (US) | 43,750.86 | 207.33 | -0.47% |
| FTSE 100 | 8,071.19 | 40.86 | 0.51% |
| HKSE | 19,557.33 | 121.52 | 0.63% |
| NASDAQ | 19,107.65 | 123.07 | -0.64% |
| Nikkei 225 | 38,842.13 | 306.43 | 0.80% |
| NZX 50 Index | 12,722.06 | 29.12 | 0.23% |
| S&P 500 | 5,949.17 | 36.21 | -0.60% |
| S&P/ASX 200 | 8,267.20 | 43.20 | 0.53% |
| SSE Composite Index | 3,370.36 | 9.48 | -0.28% |